Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial

Keil, Felix; Hartl, Maximilian; Altorjai, Gabriela; Berghold, Andrea; Riedl, Regina; Pecherstorfer, Martin; Mayrbäurl, Beate; Vries, A. de; Schuster-Kolbe, Judith; Hackl, Jutta; Füreder, Thorsten; Melchardt, Thomas; Burian, Martin; Greil, Richard

doi:10.1016/j.ejca.2021.03.051

Cited by 10 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14 Previous research investigated using a TP regimen instead of a TPF regimen to reduce toxicity in nasopharyngeal carcinoma and LAHSCC. 15,16 In recent years, researchers have also explored induction therapies, such as TP combined with cetuximab [17][18][19] and albumin paclitaxel instead of paclitaxel 20 to reduce toxic reactions.…”

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy of modified docetaxel, cisplatin, 5‐fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Zhu

et al. 2022

Head & Neck

View full text Add to dashboard Cite

BackgroundPrevious studies have investigated the value of induction chemotherapy (IC) in organ preservation strategies for head and neck cancers. This study evaluated the effectiveness of sequential IC with radiotherapy as a laryngeal preservation strategy for locally advanced hypopharyngeal carcinoma (LAHSCC).MethodsOne hundred and forty‐two consecutive patients with LAHSCC were retrospectively analyzed who received three IC regimens from 2015 to 2019.ResultsIn the TP (docetaxel plus cisplatin), TPF (TP plus 5‐fluorouracil), and TPX (TP plus capecitabine) IC groups, there were 51, 29, and 62 patients, respectively. The primary tumor objective response rates were 51%, 55.2%, and 71%, and the 3‐year survival rates with preserved larynx were 36.6%, 31.8%, and 51.2%, respectively (p = 0.03). There was no difference in overall survival and the adverse events were tolerable.ConclusionsThe TPX regimen displayed good efficacy and safety, indicating its potential as a therapeutic IC regimen for LAHSCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy of modified docetaxel, cisplatin, 5‐fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Zhu

et al. 2022

Head & Neck

View full text Add to dashboard Cite

show abstract

“…397 Nevertheless, cetuximab can be considered an effective and tolerable substitute for 5-FU in this regime, with a comparable overall response rate (ORR) and OS and slightly fewer serious adverse effects. 398 Cetuximab, paclitaxel, and carboplatin (PCC) is an alternative ICT regimen that is safe and could help induce a strong local response and promising survival. 399,400 Other monoclonal antibodies of EGFR are still under intensive investigation, including panitumumab, nimotuzumab, zalutumumab, etc.…”

Section: Egfr Inhibitorsmentioning

confidence: 99%

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Tie

Alu

et al. 2023

Sig Transduct Target Ther

101

View full text Add to dashboard Cite

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major risk factors. Based on epigenetic data, HNC is remarkably heterogeneous, and treatment remains challenging. There is a lack of significant improvement in survival and quality of life in patients with HNC. Over half of HNC patients experience locoregional recurrence or distal metastasis despite the current multiple traditional therapeutic strategies and immunotherapy. In addition, resistance to chemotherapy, radiotherapy and some targeted therapies is common. Therefore, it is urgent to explore more effective and tolerable targeted therapies to improve the clinical outcomes of HNC patients. Recent targeted therapy studies have focused on identifying promising biomarkers and developing more effective targeted therapies. A well understanding of the pathogenesis of HNC contributes to learning more about its inner association, which provides novel insight into the development of small molecule inhibitors. In this review, we summarized the vital signaling pathways and discussed the current potential therapeutic targets against critical molecules in HNC, as well as presenting preclinical animal models and ongoing or completed clinical studies about targeted therapy, which may contribute to a more favorable prognosis of HNC. Targeted therapy in combination with other therapies and its limitations were also discussed.

show abstract

“…Cetuximab is mostly used concurrently with radiotherapy either as a definitive bioradiation approach or preceded by ICT in a sequential approach, i.e., ICT followed by cetuximab/RT, and its role in induction therapy has also been studied. The TPC (docetaxel, cisplatin, cetuximab) regimen with cetuximab instead of 5-FU and the ACPF (albumin paclitaxel, cetuximab, cisplatin, 5-FU) regimen with albumin paclitaxel instead of traditional paclitaxel were more effective and better tolerated compared with the TPF regimen and could be used as an alternative to induction therapy [ 6 ]. The AGMT study [ 6 ] compared the effectiveness and safety of docetaxel combined with cisplatin and cetuximab (TPC) with TPF in the induction of LASCCHN.…”

Section: Induction Of Targeted Therapy Combined With Chemotherapymentioning

confidence: 99%

“…The TPC (docetaxel, cisplatin, cetuximab) regimen with cetuximab instead of 5-FU and the ACPF (albumin paclitaxel, cetuximab, cisplatin, 5-FU) regimen with albumin paclitaxel instead of traditional paclitaxel were more effective and better tolerated compared with the TPF regimen and could be used as an alternative to induction therapy [ 6 ]. The AGMT study [ 6 ] compared the effectiveness and safety of docetaxel combined with cisplatin and cetuximab (TPC) with TPF in the induction of LASCCHN. The results showed that the overall response rate (ORR) at 3 months (74.5% vs 64.3%) and OS rate at 400 days (86.1% vs 78.5%) in the TPC group were higher than those in the TPF group.…”

Section: Induction Of Targeted Therapy Combined With Chemotherapymentioning

confidence: 99%

“…The classic TPF regimen (docetaxel, cisplatin, 5-fluorouracil) is a standard induction chemotherapy regimen, but the toxicity problem is the biggest limitation for patients choosing to use this regimen. The exploration for an effective, low-toxicity version of the induction regimen and its clinical testing are crucial to enhance the quality of life of patients as well as prolong their survival [ 6 ]. In this review, we collected data on LAHNSCC and examined the potential of established drugs in an induction regimen to improve survival and reduce toxicity in LAHNSCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Zheng

Feng

et al. 2023

Oncol Ther

View full text Add to dashboard Cite

The optimal approach to locally advanced head and neck squamous cell carcinoma (LAHNSCC) treatment remains controversial. For non-resectable LAHNSCC, the clinical interest of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) or radiotherapy has been questioned. With the approval of immunotherapy and targeted therapy for this disease, treatment options have become more complex. Although new trial data have appeared every year, the results are still inconclusive. In this review, we provide readers with information on new strategies for LAHNSCC induction therapy, which will facilitate evidence-based decision making in LAHNSCC treatment.

show abstract

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial

Cited by 10 publications

References 28 publications

Induction chemotherapy of modified docetaxel, cisplatin, 5‐fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Induction chemotherapy of modified docetaxel, cisplatin, 5‐fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About